Byetta® Wave 4 Tracking Survey; Trends in Usage of Type II Diabetes Mellitus Therapeutics

A Survey of One Hundred Two Endocrinologists and Primary Care Physicians

(Wave 3: November 2007, Wave 2: Feb 2007, Wave 1: Dec 2006)

November 2007

Deliverable: Survey with key findings.

Study Description:

Topic	Type II Diabetes Mellitus Medications, Trends in Usage (Byetta®, Januvia™, others)
Respondent Type	Physicians
Specialty	Endocrinology (n = 51), Primary care (n = 51)
Region	United States only
Methodology	Online survey, self-administered via a Panel Intelligence website §    Duration: 20 minutes §    Size: 102 respondents §    Fielding dates: November 27 to November 28, 2007

Study Objectives:

§    Determine the current market share held by Byetta® and other medications for Type II diabetes patients.

§    Evaluate Byetta® based on physician and patient opinions.

§    Anticipate the future use and changes from current use of Byetta®.

§    Reveal side effects and cost issues Byetta® patients experience.

§    Determine impact, if any, of Januvia™ (sitagliptin) on Byetta® prescribing.

Inclusion Criteria and Respondent Demographics:

Inclusion Criteria

§    Board-certified or eligible endocrinologist or primary care physician (PCP) §    In practice between 2 and 30 years §    Spends at least 75% of professional time in clinical practice §    Currently prescribes both Byetta® and Januvia™ (any volume)

 

 

Comments on this report

There are no comments for this entry yet.

Leave a comment